{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:27:26Z","timestamp":1787610446848,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Activity of the endo-beta-glucuronidase heparanase, capable of cleaving heparan sulfate (HS), is most often elevated in many types of tumors, associating with increased tumor metastasis and decreased patients\u2019 survival. Heparanase is therefore considered to be a valid drug target, and heparanase inhibitors are being evaluated clinically in cancer patients. Heparanase 2 (Hpa2) is a close homolog of heparanase that gained very little attention, likely because it lacks HS-degrading activity typical of heparanase. The role of Hpa2 in cancer was not examined in detail. In head and neck cancer, high levels of Hpa2 are associated with decreased tumor cell dissemination to regional lymph nodes and prolonged patients\u2019 survival, suggesting that Hpa2 functions to attenuate tumor growth. Here, we examined the role of Hpa2 in normal thyroid tissue and in benign thyroid tumor, non-metastatic, and metastatic papillary thyroid carcinoma (PTC) utilizing immunostaining in correlation with clinicopathological parameters. Interestingly, we found that Hpa2 staining intensity does not significantly change in the transition from normal thyroid gland to benign, non-metastatic, or metastatic thyroid carcinoma. Remarkably, we observed that in some biopsies, Hpa2 is accumulating on the membrane (envelop) of the nucleus and termed this cellular localization NM (nuclear membrane). Notably, NM localization of Hpa2 occurred primarily in metastatic PTC and was associated with an increased number of positive (metastatic) lymph nodes collected at surgery. These results describe for the first time unrecognized localization of Hpa2 to the nuclear membrane, implying that in PTC, Hpa2 functions to promote tumor metastasis.<\/jats:p>","DOI":"10.3389\/fonc.2021.645524","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T05:51:27Z","timestamp":1618897887000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["A Pro-Tumorigenic Effect of Heparanase 2 (Hpa2) in Thyroid Carcinoma Involves Its Localization to the Nuclear Membrane"],"prefix":"10.3389","volume":"11","author":[{"given":"Itai","family":"Margulis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Naroditsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Gross-Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neta","family":"Ilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Vlodavsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Doweck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-3-030-34521-1_3","article-title":"Heparanase: Historical Aspects and Future Perspectives","volume":"1221","author":"Khanna","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00331","article-title":"Leukocyte Heparanase: A Double-Edged Sword in Tumor Progression","volume":"9","author":"Mayfosh","year":"2019","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.112.254961","article-title":"Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression","volume":"33","author":"Blich","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2017.10.007","article-title":"Proteases and glycosidases on the surface of exosomes: Newly discovered mechanisms for extracellular remodeling","author":"Sanderson","year":"2019","journal-title":"Matrix Biol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1158\/0008-5472.CAN-19-1676","article-title":"Heparanase and Chemotherapy Synergize to Drive Macrophage Activation and Enhance Tumor Growth","volume":"80","author":"Bhattacharya","year":"2020","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12967-020-02624-1","article-title":"Heparanase and the hallmarks of cancer","volume":"18","author":"Jayatilleke","year":"2020","journal-title":"J Transl Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2016-0012","article-title":"Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases","volume":"8","author":"Rivara","year":"2016","journal-title":"Future Med Chem"},{"key":"B8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/febs.13932","article-title":"Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy","volume":"284","author":"Sanderson","year":"2017","journal-title":"FEBS J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.drup.2016.10.001","article-title":"Heparanase: From basic research to therapeutic applications in cancer and inflammation","volume":"29","author":"Vlodavsky","year":"2016","journal-title":"Drug Resist Upd"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0006-0","article-title":"A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours","volume":"118","author":"Dredge","year":"2018","journal-title":"Br J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182865","article-title":"Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy","volume":"103","author":"Galli","year":"2018","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1593\/neo.06577","article-title":"Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival","volume":"8","author":"Doweck","year":"2006","journal-title":"Neoplasia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.116384","article-title":"Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity","volume":"285","author":"Levy-Adam","year":"2010","journal-title":"J Biol Chem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-34521-1_37","article-title":"Opposing Effects of Heparanase and Heparanase-2 in Head & Neck Cancer","volume":"1221","author":"Doweck","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1975","article-title":"Heparanase 2 attenuates head and neck tumor vascularity and growth","volume":"76","author":"Gross-Cohen","year":"2016","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2015.0647","article-title":"Incidental thyroid nodules and thyroid cancer: considerations before determining management","volume":"141","author":"Tufano","year":"2015","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.6437","article-title":"How Many Lymph Nodes Are Enough? Assessing the Adequacy of Lymph Node Yield for Papillary Thyroid Cancer","volume":"34","author":"Robinson","year":"2016","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30360","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed","volume":"123","author":"Haugen","year":"2017","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/0194599820904923","article-title":"Risk Factors and Outcomes of Postoperative Recurrent Well-Differentiated Thyroid Cancer: A Single Institution\u2019s 15-Year Experience","volume":"162","author":"Amin","year":"2020","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-34521-1_9","article-title":"Heparanase-The message comes in different flavors","volume":"1221","author":"Ilan","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.tibs.2017.10.007","article-title":"Opposing Functions of Heparanase-1 and Heparanase-2 in Cancer Progression","volume":"43","author":"Vlodavsky","year":"2018","journal-title":"Trends Biochem Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2000.3586","article-title":"Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member","volume":"276","author":"McKenzie","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12967-021-02770-0","article-title":"Hypermethylation of heparanase 2 promotes colorectal cancer proliferation and is associated with poor prognosis","volume":"19","author":"Zhang","year":"2021","journal-title":"J Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2004.06.008","article-title":"Id genes and proteins as promising targets in cancer therapy","volume":"10","author":"Fong","year":"2004","journal-title":"Trends Mol Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.627463","article-title":"Elucidating the consequences of heparan sulfate binding by heparanase 2","volume":"10","author":"Gross-Cohen","year":"2020","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8003","article-title":"Heparanase 2 expression inversely correlates with bladder carcinoma grade and stage","volume":"7","author":"Gross-Cohen","year":"2016","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0141139","DOI":"10.1371\/journal.pone.0141139","article-title":"The Profile of Heparanase Expression Distinguishes Differentiated Thyroid Carcinoma from Benign Neoplasms","volume":"10","author":"Matos","year":"2015","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2007.00039.x","article-title":"Mammalian heparanase: what is the message","volume":"11","author":"Vreys","year":"2007","journal-title":"J Cell Mol Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3390\/biomedicines8070188","article-title":"The Nuclear Lamina: Protein Accumulation and Disease","volume":"8","author":"Almendariz-Palacios","year":"2020","journal-title":"Biomedicines"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2014.04.015","article-title":"Nuclear translocation of heparan sulfate proteoglycans and their functional significance","volume":"1840","author":"Kovalszky","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B31","article-title":"Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis","volume":"9","author":"Xu","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2006.12.035","article-title":"Nuclear envelope","volume":"17","author":"Dultz","year":"2007","journal-title":"Curr Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-34521-1_35","article-title":"Heparanase 2 and Urofacial Syndrome, a Genetic Neuropathy","volume":"1221","author":"Roberts","year":"2020","journal-title":"Adv Exp Med Biol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.645524\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T05:51:30Z","timestamp":1618897890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.645524\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":33,"alternative-id":["10.3389\/fonc.2021.645524"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.645524","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"article-number":"645524"}}